Total Payments
$321,179
2024 Payments
$134.15
Companies
13
Transactions
96
Payment Breakdown by Category
Research$318,109 (99.0%)
Travel$1,941 (0.6%)
Food & Beverage$1,097 (0.3%)
Education$31.50 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $318,109 | 37 | 99.0% |
| Travel and Lodging | $1,941 | 5 | 0.6% |
| Food and Beverage | $1,097 | 53 | 0.3% |
| Education | $31.50 | 1 | 0.0% |
Payments by Type
Research
$318,109
37 transactions
General
$3,070
59 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arbor Pharmaceuticals, Inc. | $160,787 | 8 | $0 (2019) |
| PFIZER INC. | $122,275 | 18 | $0 (2023) |
| Eli Lilly and Company | $31,459 | 5 | $0 (2022) |
| Allergan, Inc. | $4,581 | 20 | $0 (2020) |
| AMAG Pharmaceuticals, Inc. | $1,312 | 5 | $0 (2017) |
| ABBVIE INC. | $357.82 | 15 | $0 (2024) |
| Adlon Therapeutics L.P. | $143.10 | 8 | $0 (2021) |
| Neuronetics, Inc. | $136.76 | 2 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $41.24 | 4 | $0 (2019) |
| Takeda Pharmaceuticals America, Inc. | $32.71 | 7 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $134.15 | 2 | ABBVIE INC. ($134.15) |
| 2023 | $122,318 | 20 | PFIZER INC. ($122,275) |
| 2022 | $961.30 | 5 | Eli Lilly and Company ($791.00) |
| 2021 | $22,578 | 15 | Eli Lilly and Company ($22,340) |
| 2020 | $118.42 | 5 | Adlon Therapeutics L.P. ($60.96) |
| 2019 | $160,923 | 17 | Arbor Pharmaceuticals, Inc. ($160,787) |
| 2018 | $7,796 | 7 | Eli Lilly and Company ($6,966) |
| 2017 | $6,351 | 25 | Allergan Inc. ($3,638) |
All Payment Transactions
96 individual payment records from CMS Open Payments — Page 4 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/26/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| Category: INTRAROSA | ||||||
| 08/25/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Travel and Lodging | Cash or cash equivalent | $137.30 | General |
| Category: INTRAROSA | ||||||
| 08/25/2017 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Food and Beverage | Cash or cash equivalent | $85.00 | General |
| Category: INTRAROSA | ||||||
| 08/09/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $2.85 | General |
| Category: Central Nervous System (CNS) | ||||||
| 07/31/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.88 | General |
| Category: NEUROSCIENCE | ||||||
| 07/26/2017 | Eli Lilly and Company | — | — | In-kind items and services | $1,361.65 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | ||||||
| 06/19/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.74 | General |
| Category: NEUROSCIENCE | ||||||
| 06/07/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: Central Nervous System (CNS) | ||||||
| 05/30/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.35 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2017 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: Central Nervous System (CNS) | ||||||
| 04/19/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $4.38 | General |
| Category: Central Nervous System (CNS) | ||||||
| 03/02/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $5.05 | General |
| Category: Central Nervous System (CNS) | ||||||
| 02/28/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $180.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 02/15/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: Central Nervous System (CNS) | ||||||
| 02/06/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $1,456.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 02/01/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $6.65 | General |
| Category: Central Nervous System (CNS) | ||||||
| 01/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $620.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 01/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $356.00 | Research |
| Study: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | ||||||
| 01/24/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $620.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | ||||||
| 01/24/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $356.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $160,787 | 8 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $71,593 | 16 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $50,682 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $23,818 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $6,850 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $2,612 | 4 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $976.00 | 2 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $791.00 | 1 |
About Dr. Nader Oskooilar, MD
Dr. Nader Oskooilar, MD is a Psychiatry healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1336144872.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nader Oskooilar, MD has received a total of $321,179 in payments from pharmaceutical and medical device companies, with $134.15 received in 2024. These payments were reported across 96 transactions from 13 companies. The most common payment nature is "" ($318,109).
Ad
Practice Information
- Specialty Psychiatry
- Location Newport Beach, CA
- Active Since 06/20/2005
- Last Updated 10/15/2011
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336144872
Products in Payments
- AR19 (Drug) $160,787
- NURTEC ODT (Drug) $71,593
- ZAVZPRET (Drug) $50,682
- INTRAROSA (Drug) $1,312
- VRAYLAR (Drug) $555.15
- ADHANSIA XR (Drug) $143.10
- NEUROSTAR TMS THERAPY SYSTEM (Device) $136.76
- Trintellix (Drug) $41.86
- LATUDA (Drug) $41.24
- HETLIOZ (Drug) $26.98
- SPRAVATO (Drug) $17.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Newport Beach
Dr. Hadi Estakhri, M.d, M.D
Psychiatry — Payments: $16,721
Psychiatry $16,721
Dr. Venice Sanchez, M.d, M.D
Psychiatry — Payments: $16,294
Psychiatry $16,294
Dr. Hisham Korraa, M.d, M.D
Psychiatry — Payments: $14,252
Psychiatry $14,252
Dr. Stefani Lafrenierre, Md, MD
Psychiatry — Payments: $7,842
Psychiatry $7,842
Nimisha Jain, Pa, PA
Psychiatry — Payments: $6,289
Psychiatry $6,289
Mr. Geoffrey Dibella, M.d, M.D
Psychiatry — Payments: $4,167
Psychiatry $4,167